Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80.

Article  PubMed  Google Scholar 

Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325(7):669–85.

Article  CAS  PubMed  Google Scholar 

Carbone FR, Mackay LK. Functional T cell tolerance by peripheral tissue-based checkpoint control. Nat Immunol. 2023;24(8):1224–5.

Article  PubMed  Google Scholar 

Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8(9):1069–86.

Article  PubMed  Google Scholar 

Boukouris AE, Theochari M, Stefanou D, Papalambros A, Felekouras E, Gogas H, et al. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Crit Rev Oncol Hematol. 2022;173:103663.

Article  PubMed  Google Scholar 

Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO.26 Study. JAMA Oncol. 2020;6(6):831–8.

Article  PubMed  Google Scholar 

Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–75.

Article  PubMed  PubMed Central  Google Scholar 

Jin Z, Sinicrope FA. Mismatch repair-deficient colorectal cancer: building on checkpoint blockade. J Clin Oncol. 2022;40(24):2735–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghiringhelli F, Fumet JD. Is there a place for immunotherapy for metastatic microsatellite stable colorectal cancer? Front Immunol. 2019;10:1816.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, et al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15(1):95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu S, Huang H, Sun R, Gao DS, Ye F, Huang J, et al. Synergism between IL21 and Anti-PD-1 combination therapy is underpinned by the coordinated reprogramming of the immune cellular network in the tumor microenvironment. Cancer Res Commun. 2023;3(8):1460–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55(18):3964–8.

CAS  PubMed  Google Scholar 

Georganaki M, van Hooren L, Dimberg A. Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol. 2018;9:3081.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586.

Article  CAS  PubMed  Google Scholar 

McCarthy M. Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet. 2003;361(9373):1959.

Article  PubMed  Google Scholar 

Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335–45.

Article  CAS  PubMed  Google Scholar 

Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64(11):3731–6.

Article  CAS  PubMed  Google Scholar 

Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–55.

Article  CAS  PubMed  Google Scholar 

Jia F, Li Y, Gao Y, Wang X, Lu J, Cui X, et al. Sequential-delivery nanocomplex for combined anti-angiogenesis and gene therapy against colorectal cancer. Int J Pharm. 2023;637:122850.

Article  CAS  PubMed  Google Scholar 

Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to anti-angiogenic therapy in cancer-alterations to anti-VEGF pathway. Int J Mol Sci. 2018;19(4):1232.

Article  PubMed  PubMed Central  Google Scholar 

Han YJ, Shao CY, Yao Y, Zhang Z, Fang MZ, Gong T, et al. Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies. Postgrad Med J. 2024;1184:373–81.

Article  Google Scholar 

Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt 2):117–24.

Article  CAS  PubMed  Google Scholar 

Iglesias-Escudero M, Arias-González N, Martínez-Cáceres E. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer. 2023;22(1):26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019;25(18):5449–57.

Article  CAS  PubMed  Google Scholar 

Guo Z, Jing X, Sun X, Sun S, Yang Y, Cao Y. Tumor angiogenesis and anti-angiogenic therapy. Chin Med J (Engl). 2024;137(17):2043–51.

Article  CAS  PubMed  Google Scholar 

Shaw P, Dwivedi SKD, Bhattacharya R, Mukherjee P, Rao G. VEGF signaling: role in angiogenesis and beyond. Biochim Biophys Acta Rev Cancer. 2024;1879(2):189079.

Article  CAS  PubMed  Google Scholar 

Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to Modulate Antitumor Immunity. Front Immunol. 2018;9:978.

Article  PubMed  PubMed Central  Google Scholar